

Research article

Open Access

The PhoBR two-component system regulates antibiotic biosynthesis in *Serratia* in response to phosphate

Tamzin Gristwood^{1,2}, Peter C Fineran^{1,2}, Lee Everson¹, Neil R Williamson¹ and George P Salmond*¹

Address: ¹Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK and ²Current address: Department of Microbiology & Immunology, University of Otago, PO Box 56, Dunedin, New Zealand

Email: Tamzin Gristwood - tamzin.gristwood@otago.ac.nz; Peter C Fineran - peter.fineran@otago.ac.nz; Lee Everson - le212@mole.bio.cam.ac.uk; Neil R Williamson - nrw26@mole.bio.cam.ac.uk; George P Salmond* - gpcs@mole.bio.cam.ac.uk

* Corresponding author

Published: 28 May 2009

BMC Microbiology 2009, 9:112 doi:10.1186/1471-2180-9-112

Received: 11 December 2008

Accepted: 28 May 2009

This article is available from: <http://www.biomedcentral.com/1471-2180/9/112>

© 2009 Gristwood et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Secondary metabolism in *Serratia* sp. ATCC 39006 (*Serratia* 39006) is controlled via a complex network of regulators, including a LuxIR-type (SmaIR) quorum sensing (QS) system. Here we investigate the molecular mechanism by which phosphate limitation controls biosynthesis of two antibiotic secondary metabolites, prodigiosin and carbapenem, in *Serratia* 39006.

Results: We demonstrate that a mutation in the high affinity phosphate transporter *pstSCAB-phoU*, believed to mimic low phosphate conditions, causes upregulation of secondary metabolism and QS in *Serratia* 39006, via the PhoBR two-component system. Phosphate limitation also activated secondary metabolism and QS in *Serratia* 39006. In addition, a *pstS* mutation resulted in upregulation of *rap*. Rap, a putative SlyA/MarR-family transcriptional regulator, shares similarity with the global regulator RovA (regulator of virulence) from *Yersina* spp. and is an activator of secondary metabolism in *Serratia* 39006. We demonstrate that expression of *rap*, *pigA-O* (encoding the prodigiosin biosynthetic operon) and *smaI* are controlled via PhoBR in *Serratia* 39006.

Conclusion: Phosphate limitation regulates secondary metabolism in *Serratia* 39006 via multiple inter-linked pathways, incorporating transcriptional control mediated by three important global regulators, PhoB, SmaR and Rap.

Background

Phosphate is an essential component of numerous biomolecules. Therefore, the control of intracellular phosphate concentrations is vital for bacterial survival. At least two major systems are involved in managing intracellular concentrations of inorganic orthophosphate (P_i), the preferred primary source of phosphate [1]. When P_i is abundant, the low affinity Pit transporter appears to be primarily responsible for P_i uptake [2-4]. When P_i

becomes limited, the high affinity Pst transport system (PstSCAB-PhoU) is activated, and takes over as the predominant P_i uptake system [5-8].

In *Escherichia coli* and other Enterobacteriaceae, the cellular response to P_i availability is mediated via the PhoBR two-component system. Under conditions of P_i limitation, the sensor histidine kinase PhoR is autophosphorylated [9]. PhoR then activates its cognate response

regulator, PhoB [9], which in turn activates expression of multiple genes, termed the Pho regulon, via direct binding to a conserved Pho box sequence found overlapping -35 regions in target gene promoters [10-12]. In *E. coli*, the Pho regulon is believed to consist of approximately 30 genes involved in the adaptation to survival under low P_i conditions, including *pstSCAB-phoU* and *phoBR* [1]. Phosphate regulation is controlled via similar mechanisms in *Bacillus subtilis* and *Streptomyces* species, although the consensus Pho boxes are different in each system [13,14]. Mutations in the *pstSCAB-phoU* operon result in constitutive activation of PhoR and hence, constitutive phosphorylation of PhoB [15,16]. Therefore, *pst* mutants are proposed to mimic low P_i conditions.

P_i has been found to negatively regulate the biosynthesis of antibiotics and other secondary metabolites in multiple bacterial species (reviewed in [17]). However, the complex molecular mechanisms underlying the P_i mediated regulation of secondary metabolism are not well characterised. In this study we investigate the role of the PhoBR two-component system, and P_i availability, on the regulation of antibiotic production in the Gram-negative Enterobacteriaceae, *Serratia* sp. ATCC 39006 (*Serratia* 39006). *Serratia* 39006 synthesises the red, tripyrrole antibiotic, prodigiosin (Pig; 2-methyl-3-pentyl-6-methoxy-prodigiosin) [18]. The natural physiological role of Pig in the producing organism may be as an antimicrobial agent [19]. In addition, Pig is of clinical interest due to the observed anticancer and immunosuppressive properties of this compound [20-22]. *Serratia* 39006 also produces the β-lactam antibiotic, carbapenem (Car; 1-carbapen-2-em-3-carboxylic acid) [23,24]. Both the Pig and Car biosynthetic gene clusters have been characterised (*pigA-O* and *carA-H*, respectively) [25,26].

Production of secondary metabolites in *Serratia* 39006 is controlled by a hierachial network of regulators [27]. This includes a LuxIR-type quorum sensing (QS) system (SmaIR) [25,28,29], which allows gene expression to be regulated in response to cell density via the production and detection of low molecular weight signal molecules [30]. In *Serratia* 39006, the N-acyl homoserine lactone (AHL) synthase SmaI produces two signalling molecules, N-butanoyl-L-homoserine lactone (BHL) and N-hexanoyl-L-homoserine lactone (HHL), with BHL being the major product [25]. At low cell density, SmaR acts as a transcriptional repressor of target genes [28,29]. At high cell density, and hence high BHL/HHL levels, SmaR binds BHL/HHL, resulting in decreased DNA-binding affinity with a consequent alleviation of repression. QS controls secondary metabolism in *Serratia* 39006 via at least four other regulatory genes (*carR*, *pigQ*, *pigR* and *rap*) [28,29]. The putative SlyA/MarR-family transcriptional regulator, Rap (regulator of antibiotic and pigment), is an activator

of Pig and Car production in *Serratia* 39006 [31]. Rap shares similarity with the global transcriptional regulator RovA (regulator of virulence) from *Yersina* spp. [32-34]. More than 20 additional genes have been shown to regulate secondary metabolism in *Serratia* 39006, and these are predicted to be responding to additional environmental stimuli [19,27,35,36].

Previously, we demonstrated that, in *Serratia* 39006, mutations within genes predicted to encode homologues of the *E. coli* PstSCAB-PhoU phosphate transport system resulted in over-production of both Pig (10-fold) and Car (2-fold), at the level of transcription of the biosynthetic genes [29]. In this study we investigate further the molecular mechanism by which these effects are occurring. We demonstrate that secondary metabolism in *Serratia* 39006 is upregulated in response to mutations in PstSCAB-PhoU or P_i limitation, via the PhoBR two-component system. In addition, we provide evidence that expression of the *smaI*, *pigA* and *rap* genes are activated via PhoBR in *Serratia* 39006. Hence, we propose a model in which P_i limitation increases secondary metabolism in *Serratia* 39006 via multiple, inter-linked pathways, incorporating the global transcriptional regulators PhoB, SmaR and Rap.

Results


Sequence analysis of the *pstSCAB-phoU* operon in *Serratia* 39006

Previously, *Serratia* 39006 mutants were identified which contained transposon insertions in regions sharing sequence similarity to the *pstS* and *pstA* genes from *E. coli* [29]. DNA sequencing analysis of this region revealed that *Serratia* 39006 possesses a complete *pstSCAB-phoU* operon, the organisation of which is consistent with other enteric bacteria in which a *pst* operon has been identified (Fig. 1A).

The *Serratia* 39006 *pstS* gene was predicted to encode a protein most similar to PstS from the enteric bacteria *Erwinia carotovora* ssp. *atroseptica* SCRI1043 (*Eca* 1043) (82% identity/90% similarity). The putative protein product encoded by *pstC* shared 90% identity and 95% similarity with PstC of *Eca* 1043. The *pstA* gene is predicted to encode a protein most similar to PstA of *Eca* 1043 (87% identity/92% similarity). The predicted protein encoded by *pstB* was most similar to PstB of *Eca* 1043 (88% identity/91% similarity). Finally, *phoU* was predicted to encode a protein most similar to PhoU of *Eca* 1043 (94% identity/98% similarity).

Isolation and sequence analysis of *phoBR* mutants of *Serratia* 39006

Mutations in the *pstSCAB-phoU* operon are thought to mimic growth in limiting phosphate, and hence result in constitutive activation of the Pho regulon [15]. We previ-

**Figure 1**

The *Serratia* 39006 Pst transporter is regulated via PhoBR. A) The *Serratia* 39006 *pstSCAB-phoU* genes. (B) Putative Pho boxes found upstream of the *pstS*, *phoB*, *pigA*, *smal* and *rap* genes in *Serratia* 39006. The *E. coli* Pho box consensus sequence is shown [10-12]. Conserved nucleotides are shown in bold. (C) β -Glucuronidase activity was assayed throughout growth in LB from a chromosomal *pstC::uidA* fusion in an otherwise WT background (NW201; diamonds and open bars) or a *phoB* mutant background (NW202; squares and solid bars). Bars represent β -glucuronidase assays and dashed lines represent bacterial growth.

ously showed that Pig, Car and AHL production were increased in the *pstS* mutant [29]. A possible explanation for this effect is that *pigA*, *carA* and *smal* are regulated via the *Serratia* 39006 Pho regulon.

Random transposon insertions in the *phoBR* operon were isolated based on their lack of hyperpigmentation when grown on P_i -limiting media. Growth on P_i -limiting media results in increased Pig production in the wild-type (WT; throughout this manuscript WT refers to the LacA parental strain) [29]. Potential *phoBR* mutants were then checked for their loss of alkaline phosphatase activity (*phoA*, encoding alkaline phosphatase, is a conserved Pho regulon gene [1,37]) and the sequence of the operon was determined, as described in Methods. The *phoB* gene was predicted to encode a 229 amino acid (aa) protein with highest similarity to PhoB from *Eca* 1043 (96% identity/98% similarity). The *phoR* gene was located 28 bp downstream of *phoB*, and was predicted to encode a 440 aa protein sharing the highest degree of similarity to *Eca* 1043 PhoR (87% identity/90% similarity).

PhoB regulates expression of *pstC* in *Serratia* 39006

In *E. coli*, the *pst* operon is activated via direct binding of PhoB to a conserved Pho box upstream of *pstS* [10-12]. As *Serratia* 39006 is a member of the Enterobacteriaceae, we identified potential Pho boxes based on the *E. coli* consen-

sus sequence. A potential Pho box was identified within the *pstS* promoter region of *Serratia* 39006, centred 122 bp upstream of the *pstS* start codon (Fig. 1B). This suggested that, as could be expected based on regulation of the *pstSCAB-phoU* genes in other bacteria, the *pstSCAB-phoU* genes in *Serratia* 39006 may be regulated by PhoB. A putative Pho box was also identified upstream of *phoB* (Fig 1B), centred 68 bp upstream of the *phoB* start codon, suggesting that *phoBR* may be auto-regulated via the putative Pho box.

β -Glucuronidase activity produced from a chromosomal *pstC::uidA* transcriptional fusion was measured in the presence or absence of a secondary mutation in *phoB*. The *pstC::uidA* fusion strain does not contain a functional Pst transporter and is therefore believed to mimic low phosphate conditions. These data showed that, in the presence of functional PhoB, *pstC* was expressed constitutively throughout growth (Fig. 1C). Expression was dramatically reduced following inactivation of *phoB*, indicating that PhoB activates expression of the *pst* operon in *Serratia* 39006 (Fig. 1C).

Insertions within *phoBR* abolish upregulation of secondary metabolism and QS in the *pstS* mutant

It was hypothesised that the upregulation of Pig, Car and QS in a *Serratia* 39006 *pst* mutant was mediated via the

PhoBR two-component system. Assessment of Pig, Car and QS phenotypes in *pstS*, *phoB* and *pstS, phoR* double mutants confirmed that *phoB* and *phoR* were responsible for the upregulation of secondary metabolism in a *pstS* mutant background. The *pstS* mutant was increased for Pig (9-fold), Car (2-fold) and AHL (2.5-fold) production compared with the WT (Fig. 2). However, the *pstS, phoB* and *pstS, phoR* double mutants were restored to WT levels for Pig, Car and AHL production in LB (Fig. 2). Single *phoB* or *phoR* mutations had no effect on Pig, Car or AHL production (Fig. 2). As it has been previously shown that upregulation of Car in response to a *pst* mutation is mediated via the upregulation of QS [29], we focused on the effects on *pigA* and *smaI* expression for the remainder of this study.

Insertions within phoBR abolish transcriptional upregulation of pigA and smaI in the *pstS* mutant

Phenotypic analysis showed that PhoBR are required for the upregulation of secondary metabolism and QS in response to mutation of the *pstSCAB-phoU* operon (described above). To confirm that these effects are exerted at the transcriptional level, primer extension analysis was used to assess levels of the *pigA* and *smaI* transcripts throughout growth in WT, *pstS* mutant and *pstS, phoB* double mutant strains. The abundance of *pigA* mRNA in the *pstS, phoB* double mutant was restored to levels similar to those displayed in WT *Serratia* 39006 (Fig. 3A). A chromosomal *pigA::lacZ* transcriptional fusion was used to confirm this result; a 3-fold increase in *pigA* transcription was observed in a *pstS* mutant, this was restored to WT levels following a secondary mutation in *phoB* or

phoR (Fig. 3B). The upregulation of *smaI* transcription in the *pstS* mutant was also abolished by a *phoB* mutation (Fig. 3C). This is consistent with the hypothesis that PhoB, either directly or indirectly, activates expression of *pigA* and *smaI* in response to constitutive phosphorylation by PhoR as a result of the *pstS* insertion.

Insertions within *pstSCAB-phoU* result in increased transcription of *rap*

A complex network of regulators controls secondary metabolism in *Serratia* 39006 [27]. Therefore, it was possible that the effects on Pig and AHL production, in response to a *pst* mutation, were mediated via one or more of these regulators. To test if the effect on *smaI* and *pigA* transcription was mediated through any of the known secondary metabolite regulators, the expression of chromosomal *lacZ* transcriptional fusions in *pigP*, *pigQ*, *pigR*, *pigS*, *pigT*, *pigV*, *pigW*, *pigX*, *pigZ*, *rap* and *carR* was assessed throughout growth in the presence or absence of a *pstS::mini-Tn5Sm/Sp* insertion (data not shown). No effect was seen on any of the regulatory genes except for *rap*. The expression of *rap* was increased by 1.4-fold in the *pstS* mutant (Fig. 4A). Rap is a putative SlyA/MarR-family transcriptional regulator. As expression of *rap* is known to be regulated by QS [28], the effect of a *pstC* mutation on expression of a *rap::lacZ* transcriptional fusion was assessed in a *smaI* mutant background. A mutation within the *pstSCAB-phoU* operon was still able to activate *rap* transcription (1.5-fold increase), in the absence of functional *smaI*, indicating that this effect is via both QS -dependent and -independent pathways (Fig. 4B).




Figure 2
The effects of a *pstS* mutation on secondary metabolism and QS are occurring via PhoBR. (A) Pig, (B) Car and (C) AHL production were measured from WT, *pstS* mutant (ROP2), *phoR* mutant (BRI), *phoB* mutant (BR9), *pstS, phoR* double mutant (PCF60) and *pstS, phoB* double mutant (PCF59) cells. Production was assayed from cells grown to early stationary phase in LB.




Figure 3
A *pstS* mutation effects transcription of *pigA* and *smal* via PhoBR. Primer extension analysis was used to measure the level of (A) *pigA* or (C) *smal* transcripts in WT, *pstS* mutant (ROP2), or *pstS, phoB* (RBR9) double mutant strains throughout growth in LB. (B) β -Galactosidase activity was measured from a chromosomal *pigA::lacZ* fusion in an otherwise WT background (NW60), or in *pstS* (PCF76), *phoR* (PCF75), *phoB* (PCF74), *pstS, phoR* double (PCF78) or *pstS, phoB* double (PCF77) mutant backgrounds. Activity was assayed from cells grown to early stationary phase in LB.

PhoB activates expression from the *pigA* and *rap* promoters in an *E. coli* system

To investigate the control of the *pigA*, *rap* and *smal* promoters in more detail, an *E. coli* plasmid-based system was used (described in Methods). β -Galactosidase activity was measured from *E. coli* strains carrying the *pigA*, *rap* and *smal* promoters, inserted upstream of a promoterless *lacZ* gene (encoded by vectors pTA15, pTA14 or pTG27, respectively) in the presence or absence of *Serratia* 39006 PhoB, encoded by plasmid pTA74. Transcription from the *pigA*





Figure 4
B Expression of *rap* is activated following mutation of the *pstSCAB* operon. β -Galactosidase activity was assayed throughout growth from a chromosomal *rap::lacZ* fusion in (A) an otherwise WT background (RAPL; diamonds and open bars) or a *pstS* mutant background (PCF45; squares and solid bars), or (B) a *smal* (ISRL; diamonds and open bars) or *pstC, smal* (TG71; squares and solid bars) mutant background. In both graphs, bars represent β -galactosidase assays and dashed lines represent bacterial growth.

and *rap* promoters increased in the presence of pTA74, indicating that these genes may be activated by PhoB (Fig. 5). Unfortunately, the level of expression from the *smal* promoter was negligible in this system (data not shown). Therefore, it was not possible to determine whether PhoB

**Figure 5**

In *E. coli*, *Serratia 39006* PhoB can activate expression from the *pigA* and *rap* promoters. β -Galactosidase activity was measured from *E. coli* cells grown in LB carrying plasmid pTA15 or pTA14 (containing the *pigA* or *rap* promoters respectively cloned upstream of a promoterless *lacZ* gene) and either an empty vector control (pQE-80L) (solid bar) or pTA74, encoding PhoB (unfilled bar).

was modulating transcription from the *smaI* promoter. In the *E. coli* system, the degree of activation from both the *pigA* and *rap* promoters in the presence of PhoB is comparable with the levels of activation observed using chromosomal *pigA::lacZ* and *rap::lacZ* transcriptional fusions as a result of *pstS/pstC* mutation in *Serratia 39006* (Fig. 3B & Fig. 4). Putative weak Pho boxes were identified within the promoter regions of *pigA* and *smaI*, overlapping the predicted -35 sequences and centred 28 bp and 34 bp, respectively, upstream of the transcriptional start sites, which were previously mapped by primer extension [29] (Fig. 1B). A putative weak Pho box was also identified within the *rap* promoter, centred 148 bp upstream of the *rap* start codon (Fig. 1B). The presence of putative Pho boxes suggest that PhoB may directly activate expression of *pigA*, *smaI* and *rap*, although this has not yet been shown experimentally. In the *E. coli* reporter assays described, it is possible that *Serratia 39006* PhoB may show activity in the absence of the cognate *Serratia 39006* histidine kinase, PhoR, due to cross-regulation by non-cognate *E. coli* histidine kinases, or as a result of low level activity of the unphosphorylated *Serratia 39006* PhoB.

P_i* regulates secondary metabolism and QS in *Serratia 39006

In other species, PhoBR upregulates expression of multiple genes when the cell is starved for *P_i*. As *P_i* has been shown to control secondary metabolism in multiple species [17], we investigated whether secondary metabolism and QS in *Serratia 39006* were also modified by *P_i* limitation. Growth of *Serratia 39006* in phosphate-limiting medium (PL medium) without the addition of 5 mM KH₂PO₄ resulted in an increase in Pig (6-fold) and AHL (2-fold) production (Fig. 6A &6B), reminiscent of the effects of *pstS* mutations. β -Galactosidase activity from strains containing chromosomal *pigA::lacZ*, *smaI::lacZ* and *rap::lacZ* fusions grown in PL medium without the addition of 5 mM KH₂PO₄ was also assessed. *P_i* limitation resulted in increased transcription of *pigA* (2-fold) and *smaI* (5-fold) compared with *P_i* replete conditions (Fig. 7A &7B), although there was not a clear increase in *rap* transcription (Fig. 7C). These experiments demonstrate that low *P_i*, like *pstSCAB-phoU* mutations, controls the transcription of *pigA* and *smaI* to up-regulate secondary metabolism and QS. However, in each instance, the fold increase in response to *P_i* limitation is lower (by approxi-




Figure 6
 P_i limitation affects secondary metabolism and QS. (A) Pig and (B) AHL production in WT cells were measured throughout growth in phosphate-limiting medium with (squares) or without (triangles) the addition of 5 mM KH_2PO_4 . In all graphs, solid lines represent Pig or AHL assays and dashed lines represent bacterial growth.




Figure 7
The effect of P_i limitation on *pigA*, *smal* and *rap* transcription. β -Galactosidase activity was measured from a chromosomal (A) *pigA::lacZ* (MCP2L), (B) *smal::lacZ* (LC13) or (C) *rap::lacZ* (RAPL) strain throughout growth in phosphate-limiting medium with (squares) or without (triangles) the addition of 5 mM KH_2PO_4 . In all graphs, solid lines represent β -galactosidase assays and dashed lines represent bacterial growth.

mately 35%) than that observed in a *pst* mutant. As the increase in *rap* transcription in a *pst* mutant is below 2-fold, a lesser change, in response to P_i limitation, may be below the level of detection.

We predicted that a *pstS* mutation would be epistatic to the effects of P_i on secondary metabolism and QS. In a *pstS* mutant, P_i limitation did not result in an increase in maximal Pig production (Fig. 8A), although slightly premature production of Pig was observed (data not shown). In addition, P_i limitation resulted in only a small (1.3-fold) increase in AHL production in a *pstS* mutant (Fig. 8B). Taken together, the data suggest that in *Serratia* 39006, as in other bacteria, mutation of *pstS* mimics the effect of P_i-limiting media. However, other mechanisms also appear to play a role, facilitating the small increase in AHL production observed in response to P_i limitation despite the absence of a functional PstSCAB-PhoU system.

Discussion

There are multiple studies identifying environmental factors that effect Pig production in *Serratia* spp., including the effects of salt concentration, temperature, oxygen availability and multiple metal ion concentrations [27]. However, the molecular mechanism underlying most of these responses has not been elucidated. Here, we investigate the molecular mechanism by which P_i limitation

affects secondary metabolism in the enteric bacteria *Serratia* 39006.

It was previously shown that a *pstS* mutation in *Serratia* 39006 resulted in the upregulation of QS and secondary metabolism [29]. Here, we demonstrate that these effects are occurring via the PhoBR two-component system, since a secondary mutation in *phoBR* abolished the effects of a *pstS* mutation. In addition, we confirm that QS and secondary metabolism are upregulated in response to P_i limitation, and that this is occurring primarily via the PstSCAB-PhoU transport system. We also demonstrate that expression of *rap* is upregulated in response to a *pstS* mutation. Rap is an activator of Pig and Car, and a repressor of surfactant production and swarming motility, in *Serratia* 39006 [19,29]. Rap shares similarity with the SlyA/MarR-family global transcription factor, RovA, which regulates genes required for host colonization in *Yersinia* spp. [32-34]. Therefore, our results indicate that three global transcriptional regulators, Rap, SmaR and PhoB, are involved in mediating the effects of P_i limitation on secondary metabolism in *Serratia* 39006.

A mutation of the *pstSCAB-phoU* genes resulted in a clear increase in Pig and AHL production, and a clear increase in *pigA*, *smaI* and *rap* transcription. However, following P_i limitation, the effects on secondary metabolism and gene




Figure 8

A *pstS* mutant is largely unresponsive to P_i limitation. (A) Pig and (B) AHL production was measured from a *pstS* mutant (ROP2) grown to early stationary phase in phosphate-limiting medium with (open bars) or without (solid bars) the addition of 5 mM KH₂PO₄.

expression were less dramatic. The degree of activation of Pig and AHL production, and *pigA* transcription, was approximately 35% lower following P_i limitation than the levels of activation observed in a *pstS* mutant. In addition, a clear increase in *rap* transcription was not observed following P_i limitation. It is possible that this reduced effect is due to the fact that a *pstS* mutant is constitutively mimicking extreme P_i limitation. However, when WT cells are transferred to phosphate limiting media, there may be phosphate carry over from the initial inoculum, and the cells may utilise existing intracellular phosphate stores, for example inorganic polyphosphate, before phosphate starvation occurs. As the increase in *rap* transcription in a *pstS* mutant is below 2-fold, we believe that a 35% reduction in activation, in response to P_i limitation, may be undetectable. An alternative explanation could be that *rap* is induced via PhoBR, but not in response to P_i limitation. Previously, PhoBR has been shown to activate expression of the *asr* (acid shock RNA) gene, but P_i limitation did not activate *asr* expression [38]. In addition, there is also evidence that PhoB can be activated by non-partner histidine kinases, in the absence of PhoR [39]. This has lead to the hypothesis that PhoBR may activate genes in response to a variety of environmental cues, in addition to P_i limitation [39].

It may not be entirely accurate to describe the effect of a *pstS* mutation, or P_i limitation, on QS as 'upregulation'. For QS to function correctly, it is the absolute concentrations of the AHL signal molecule that is critical, not the amount per cell [30]. Due to the growth defect observed following a *pstS* mutation or P_i limitation, the amount of AHL per cell is increased, but the absolute value remains comparable to WT/P_i excess conditions. Therefore, it may be more accurate to state that the upregulation of *smaI* transcription, following *pstS* mutation or P_i limitation, allows maintenance of QS regulon control despite the reduced growth rate. This idea is supported by the fact that although *carR*, *pigQ*, *pigR* and *rap* are all regulated by QS in *Serratia* 39006 [28,29], only *rap* transcription is upregulated in response to a *pstS* mutation. Our experiments indicate that, in response to a *pst* mutation, *rap* is activated independently of QS, and that activation may be mediated via PhoB.

Activation of *carA* expression, following *pstS* mutation, was previously reported to be dependent on the upregulation of QS [29]. However, as Rap is also an activator of *carA* transcription [29], it is possible that Rap, rather than QS, is responsible for the activation of *carA* following a *pstS* mutation. We propose that a dual mechanism, involving (1) the alleviation of SmaR repression at lower cell density, via upregulation of *smaI*, and (2) increased levels of Rap via PhoB mediated transcriptional activation, is responsible for the increase in *carA* expression fol-

lowing *pstS* mutation. In the absence of AHL (and hence constitutive SmaR repression), *carA* transcription is essentially abolished [29] and hence, further activation by Rap, in response to a *pstS* mutation, might not be possible.

Based on our data, we propose a model by which P_i limitation results in upregulation of secondary metabolism via multiple inter-linked pathways (Fig. 9). In response to P_i limitation, or following mutation of the *pstSCAB* genes, PhoB is activated by phosphorylation [9,15,16]. PhoB~P can then activate expression of genes involved in the *Serratia* phosphate response which includes *smaI*, *pigA* and *rap*. Activation of *pigA* expression causes increased Pig production. Upregulation of *smaI* allows appropriate derepression by SmaR [28,29]. This allows activation of *pigA*, *carA* and *rap* transcription. Rap, which is activated via QS and the phosphate response, can then further activate *carA* and *pigA* transcription. This results in upregulation of both Car and Pig production via multiple pathways.

Multiple studies have linked P_i limitation to enhanced secondary metabolite production [17]. However, the complex molecular mechanisms underlying phosphate-mediated regulation have proven difficult to elucidate. Extensive studies in *Streptomyces* species have shown that PhoPR (PhoBR) activates secondary metabolism in response to P_i limitation, including biosynthesis of undecylprodigiosin, a tripyrrole closely related to Pig [40,41]. However, in *Streptomyces*, inactivation of PhoP or deletion of *phoPR* also activates secondary metabolism [41]. In contrast, deletion of *phoB* and/or *phoR* in *Serratia* 39006 had no impact on secondary metabolism, demonstrating clear differences between the regulatory mechanisms employed by these distantly related bacteria. Although the requirement for increased secondary metabolism under conditions of phosphate limitation is unclear, it has been proposed that enhanced secondary metabolism allows the production of compounds which may, for example, directly antagonise other microorganisms or act as signalling molecules, thereby providing producing organisms with a competitive advantage under nutrient deprived conditions [40,42,43].


Conclusion

In conclusion, we have established that via the global transcriptional regulators PhoB, SmaR and Rap, multiple inter-linked pathways are acting to upregulate secondary metabolism in *Serratia* 39006 under conditions of P_i limitation, highlighting the importance of Pig and Car production under these conditions.

Methods

Bacterial strains, plasmids, phage and culture conditions

Bacterial strains and plasmids are listed in Additional File 1[44-49]. *Serratia* sp. ATCC 39006 derivative strains were

**Figure 9**

The proposed mechanism by P_i limitation can upregulate secondary metabolism in *Serratia 39006*. In response to P_i limitation (or *pstS* mutation), PhoR activates PhoB by phosphorylation. Active PhoB can then activate transcription of *smal*, *pigA* and *rap* (indicated using solid arrows). Upregulation of *smal* results in activation of the QS regulated genes (*pigA*, *carA* and *rap*), via AHL mediated SmaR derepression (indicated using dashed arrows). Rap then further activates *carA* and *pigA* expression (indicated using solid arrows). This results in upregulation of Pig and Car production.

grown at 30°C and *E. coli* strains were grown at 37°C in Luria broth (LB; 5 g l⁻¹ yeast extract, 10 g l⁻¹ bacto tryptone

and 5 g l⁻¹ NaCl), minimal media (0.1% w/v (NH₄)₂SO₄, 0.41 mM MgSO₄, 0.2% w/v glucose, 40 mM K₂HPO₄, 14.7 mM KH₂PO₄, pH 6.9–7.1) or in phosphate limiting (PL) media (0.1% w/v (NH₄)₂SO₄, 0.41 mM MgSO₄, 0.2% w/v glucose, 0.1 M HEPES, pH 6.9–7.1 ± 5 mM KH₂PO₄) in shake flasks at 300 rpm, or on plates supplemented with 1.5% (w/v) agar (LBA). For the *phoBR* mutagenesis screen, *Serratia* 39006 was grown on PGM agar plates (5 g l⁻¹ bacto peptone, 1% v/v glycerol and 1.5% w/v agar). Bacterial growth (OD₆₀₀) was measured in a Unicam Helios spectrophotometer at 600 nm. When required, media were supplemented with antibiotics at the following final concentrations; kanamycin 50 µg ml⁻¹ (Km), spectinomycin 50 µg ml⁻¹ (Sp), ampicillin 100 µg ml⁻¹ (Ap), and tetracycline 35 µg ml⁻¹ (Tc). The generalised transducing phage φOT8 was used for transduction of chromosomal mutations as described previously [25].

DNA manipulations

All molecular biology techniques, unless stated otherwise, were performed by standard methods [50]. Oligonucleotide primers were obtained from Sigma Genosys and are listed in Table 1. DNA sequencing was performed at the DNA Sequencing Facility, Department of Biochemistry, University of Cambridge, analysed using GCG (Genetics Computer Group, University of Wisconsin) and compared with GenBank DNA or non-redundant protein sequence databases using BLAST [51].

Sequencing of the *pstSCAB-phoU* operon

Preliminary sequence analysis indicated the mini-Tn5Sm/Sp insertions in strains ROP2 and KHC5 were in *pstS* and *pstA* respectively [29]. To determine the full sequence of *pstS* and its surrounding genes, a *Serratia* 39006 *PstI* subgenomic library was created in pBluescript II KS+. One clone containing *pstS* was analysed further and was named pPST1. The *pst* region was sequenced via a 'primer walking' technique using primers PST1, PST2, PST3, PST4, PST5, PSTSLN, PSTSRN. To complete the *pstSCAB-phoU* operon, a 2.1 kbp region of *pstSCA* was PCR amplified with the primers NW244 and NW245, and then sequenced using primers NW244, NW245, NW246 and NW247. Random primed PCR was used to extend the *phoU* sequence obtained from primer walking of pPST1, as described previously [48]. Gene specific primer NW250 was used in two separate random primed PCR reactions, one with PF106, PF107, PF108 [48], and a second with NW225, NW226, NW227. The products generated were then amplified with the nested primer PF109 or NW251, respectively and the resulting PCR products sequenced with primer NW251.

Transposon mutagenesis screen for *phoBR* mutants

To isolate *phoBR* mutants, *Serratia* 39006 strain LacA was subjected to a random transposon mutagenesis by conju-

Table I: Oligonucleotide primers used in this study

Name	5'-3' sequence	Description	Restriction site
HS34	GCTGACTCATAAATATCTGACTG	<i>pigA</i> , primer extension oligo	
HS36	GCGAAAATAGCTCGGCTGATCTC	<i>smal</i> , primer extension oligo	
HS60	GTCTATATCGGCATCTGTTCC	<i>carA</i> , primer extension oligo	
KML	CCAGTAAGTTTCCAGTAGGTTGG	F primer for Km ^R gene of miniTn5KmI	
KMR	CCGAGCTTGGTACCCAGTC	R primer for Km ^R gene of miniTn5KmI	
NW225	GACCACACGTCGACTAGTCNNNNNNNNNACTG	Random primed PCR primer 1	
NW226	GACCACACGTCGACTAGTCNNNNNNNNNATGAC	Random primed PCR primer 2	
NW227	GACCACACGTCGACTAGTCNNNNNNNNNGTCTC	Random primed PCR primer 3	
NW244	CGTCTGCCAGGTGCTATTGGTTATG	<i>pstSCAB</i> region sequencing primer	
NW245	GGATAACGAAGTGAACAGCAAC	<i>pstSCAB</i> region sequencing primer	
NW246	GCATCCTGGCCGAGCATAAGCAAG	<i>pstSCAB</i> region sequencing primer	
NW247	GCGACGCATGCGATAAGCTG	<i>pstSCAB</i> region sequencing primer	
NW250	CATTACTGCGATGCACAATCG	<i>phoU</i> sequencing primer	
NW251	GTGACGATTGATGAAGCTTGTG	<i>phoU</i> sequencing primer	
OTG124	ATCAGAGAATTCTACTAATTGGAGTCATTACCG	F primer for pTG27, <i>smal</i> promoter construct	EcoRI
OTG125	ATCAGAAAGCTTAGTCTATCATTATAGCGTTCC	R primer for pTG27, <i>smal</i> promoter construct	HindIII
PF42	GCATAAGCTTCCATCACTACTCC	R primer for pTA14, <i>rap</i> promoter construct	HindIII
PF43	GTAAGAATTGCGATGTTAGAAAC	F primer for pTA14, <i>rap</i> promoter construct	EcoRI
PF154	GATGAATTCAAGGAGCACGGATGGCAAGACGTATTTTG	F primer for pTA74, PhoB expression construction	EcoRI
PF155	TCTAACGCTTCAGTAACCGCGTCGAG	R primer for pTA74, PhoB expression construction	HindIII
PF180	TTTGAATTGCTAGTTGGGAGATTTTC	F primer for sequencing <i>phoR</i>	EcoRI
PF182	TTTAAGCTTGCTGCCGGACCGC	R primer for sequencing <i>phoR</i>	HindIII
PHORL	GCGTTAGTTGGGAGATTTTC	F <i>phoR</i> primer	
PHORR	CTCCCCAAACTAACGCTGTC	R <i>phoR</i> primer	
PST1	CAGCGTCTGCCAGGTGC	<i>pstS</i> sequencing primer	
PST2	GTCCACGTTGCTGAG	<i>pstA</i> sequencing primer	
PST3	CCAGCTTACCCAGAGCAACATG	<i>pstB</i> sequencing primer	
PST4	CAGAGTGTAGTTGCAGG	<i>pstS</i> sequencing primer	
PST5	CGAGCAACAGCCAGTAG	<i>pstA</i> sequencing primer	
PSTS1N	CAACAGGATAAAGGTAGTGGAGG	<i>pstS</i> sequencing primer	
PSTS1RN	CTGCACGGTCTGGTCG	<i>pstS</i> sequencing primer	
T3	CGCGCAATTAAACCCCTCACTAAAG	pBluescript II KS+ sequencing primer	
T7	GCGCGTAATACGACTCACTATAG	pBluescript II KS+ sequencing primer	

gation with *E. coli* S17-1 *λpir* harbouring plasmid pUTmini-Tn5Km1 as described previously [25]. Ten thousand mutants were picked onto glucose minimal medium plates and replica-plated onto PGM agar. Colonies that did not exhibit a hyper-pigmented phenotype were selected, based on the rationale that if hyper-pigmentation was not induced in response to P_i limitation, it might be due to an insertion in *phoBR* (strains BR1 and BR9 were isolated using this screen). The *pstS*::miniTn5Sm/Sp was transduced into non-P_i responsive mutants, and non-hyperpigmented mutants were then selected (strains RBR1 and RBR9 were selected following this screen). This suggested that these uncharacterised insertions had disrupted a regulatory element(s) common to *pstS* mutants and P_i limitation effects. The possibility that *phoBR* had been disrupted was investigated further by measuring alkaline phosphatase activity, encoded by *phoA*, which is a well conserved member of enteric Pho regulons [1]. Mutants RBR1 and RBR9 did not produce elevated levels of alkaline phosphatase as observed in the *pstS* mutant (data not

shown). Sequence analysis, described below, confirmed that the insertions in BR1 and BR9 were within *phoR* and *phoB* respectively.

Sequencing of the *phoBR* operon

To determine the site of the transposon insertion in strain BR1, chromosomal DNA was digested with EcoRV and ligated into pBluescript II KS+. The ligation was used as template in a single-primer-site PCR using primers KML and KMR that anneal to the 5' and 3' ends of mini-Tn5Km1 respectively in combination with primers T3 and T7. Sequencing of the resultant PCR products revealed that BR1 contained an insertion within a gene similar to *phoR* from *E. coli*. A further PCR using chromosomal DNA from the BR9 mutant with primers PHORL and PHORR (homologous to *phoR* 5' and 3' ends) and primers KML and KMR demonstrated that BR9 contained an insertion within a gene with similarity to *phoB* from *E. coli*. To further confirm the *phoBR* sequence, PCR products of *phob* and *phoR* were generated with primer pairs PF154/PF155

and PF180/PF182 respectively and sequenced on both strands from independent products.

Construction of a plasmid (pTA74) that expresses native PhoB

A construct that enabled expression of native, untagged PhoB was created as outlined below. The *phoB* gene was amplified by PCR, using primers PF154 and PF155, which contain *Eco*RI and *Hind*III restriction sites, respectively. Additionally, primer PF154 contains a consensus ribosome-binding site (RBS, AGGAGGA). The PCR fragment of *phoB* was cloned into pQE-80L, previously digested with the enzymes *Eco*RI and *Hind*III. The resulting plasmid, pTA74, was confirmed by DNA sequencing. Expression of plasmid pTA74 in *E. coli* was induced with 1 mM IPTG.

Construction of promoter::lacZ fusions and assay conditions

Plasmid pTA15 was constructed as described previously [48]. The *rap* and *sma*I promoter regions were cloned into the promoterless *lacZ* plasmid pRW50 [49] to give the plasmid constructs pTA14 and pTG27, respectively. Plasmid pTG27 was constructed by cloning an *Eco*RI/*Hind*III digested PCR product (generated using forward primer OTG124 and reverse primers OTG125) into *Eco*RI/*Hind*III digested pRW50. Plasmid pTA14 was constructed by cloning an *Eco*RI/*Hind*III digested PCR product (generated using forward primer PF43 and reverse primer PF42) into *Eco*RI/*Hind*III digested pRW50. All constructs were confirmed by DNA sequencing.

Promoter activity assays were performed in *E. coli* DH5 α cells as described in [48]. Briefly, DH5 α cells were transformed with the promoter::*lacZ* construct (pTA14, pTA15 or pTG27) and either pTA74 (encoding native PhoB) or the empty vector control, pQE-80L. The resulting strains were grown in LB containing Ap, Tc and 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG). At late exponential phase, 1 ml samples were assayed for β -galactosidase activity.

Prodigiosin, carbapenem, AHL, β -galactosidase, β -glucuronidase and alkaline phosphatase assays

The assays for Pig and Car were performed as described previously [29]. Pig production was plotted as (A_{534} ml $^{-1}$ OD $_{600}^{-1}$). Detection of AHLs was performed using the *Serratia* LIS bioassay described in [25]. β -Galactosidase activity was determined as described previously [28] and was represented as (ΔA_{420} min $^{-1}$ ml $^{-1}$ OD $_{600}^{-1}$). β -Glucuronidase activity was determined as for β -galactosidase activity except that reactions were performed in GUS buffer (50 mM NaPO $_{4,2}$, 1 mM EDTA, 5 mM DTT, pH 7.0), using the substrate *p*-nitrophenyl β -glucuronide (PNPG; 10 mM), and measured at A_{405} . β -Glucuronidase activity was represented as (ΔA_{405} min $^{-1}$ ml $^{-1}$ OD $_{600}^{-1}$). Alkaline phos-

phatase activity was assayed as described previously [52]. Results presented are the mean \pm the standard deviation of three independent experiments, unless stated otherwise.

Primer Extension and RNA studies

RNA was extracted from *Serratia* 39006 and primer extension analysis for the *pigA* and *smaI* transcripts was performed as described previously [28,29]. All primer extension reactions were performed with 25 μ g of total RNA and 0.2 pmol of the appropriate 32 P-labelled primer. Oligonucleotide primers HS34 and HS36 were used in primer extension reactions for *pigA* and *smaI* respectively.

Authors' contributions

TG drafted the manuscript, participated in design of the study and performed all experiments that are not credited to the additional authors, listed below. PF generated multiple strains (PCF# strains) and plasmids used in the study, participated in sequencing *phoBR*, participated in design of the study and critically reviewed the manuscript. LE isolated strains BR1 and BR9, performed primer extension analysis, participated in sequencing *phoBR* and *pstSCAB-phoU*, and participated in design of the study. NW generated strain NW201 and NW202, measured *pstC::uidA* expression and participated in sequencing of *pstSCAB-phoU*. GS conceived of the study and participated in the design and coordination of the study.

Additional material

Additional file 1

Bacterial strains, phages and plasmids used in this study. A list of strains, phage and plasmids used in this study.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2180-9-112-S1.doc>]

Acknowledgements

We thank all members of the Salmon group for helpful discussions, I. Foulds for technical assistance and Corinna Richter for the identification of strain PCF58A9. This work was supported by the BBSRC, UK. TG and LE were supported by BBSRC studentships.

References

- Wanner BL: **Phosphorous assimilation and control of the phosphate regulon.** In *Escherichia coli and Salmonella: Cellular and Molecular Biology Volume 1*. Edited by: Neidhart RCI, Ingraham JL, Lin ECC, Low KB, Magasanik B, Reznikoff WS, Riley M, Schaechter M, Umbrager HE. American Society for Microbiology, Washington, DC; 1996:1357-1381.
- Harris RM, Webb DC, Howitt SM, Cox GB: **Characterization of PitA and PitB from Escherichia coli.** *J Bacteriol* 2001, **183**(17):5008-5014.
- Rosenberg H, Gerdes RG, Chegwidden K: **Two systems for the uptake of phosphate in Escherichia coli.** *J Bacteriol* 1977, **131**(2):505-511.

4. Rosenberg H, Gerdes RG, Harold FM: **Energy coupling to the transport of inorganic phosphate in *Escherichia coli* K12.** *Biochem J* 1979, **178**(1):133-137.
5. Amemura M, Makino K, Shinagawa H, Kobayashi A, Nakata A: **Nucleotide sequence of the genes involved in phosphate transport and regulation of the phosphate regulon in *Escherichia coli*.** *J Mol Biol* 1985, **184**(2):241-250.
6. Surin BP, Rosenberg H, Cox GB: **Phosphate-specific transport system of *Escherichia coli*: nucleotide sequence and gene-polypeptide relationships.** *J Bacteriol* 1985, **161**(1):189-198.
7. Webb DC, Rosenberg H, Cox GB: **Mutational analysis of the *Escherichia coli* phosphate-specific transport system, a member of the traffic ATPase (or ABC) family of membrane transporters. A role for proline residues in transmembrane helices.** *J Biol Chem* 1992, **267**(34):24661-24668.
8. Willsky GR, Malamy MH: **Characterization of two genetically separable inorganic phosphate transport systems in *Escherichia coli*.** *J Bacteriol* 1980, **144**(1):356-365.
9. Yamada M, Makino K, Amemura M, Shinagawa H, Nakata A: **Regulation of the phosphate regulon of *Escherichia coli*: analysis of mutant *phoB* and *phoR* genes causing different phenotypes.** *J Bacteriol* 1989, **171**(10):5601-5606.
10. Kimura S, Makino K, Shinagawa H, Amemura M, Nakata A: **Regulation of the phosphate regulon of *Escherichia coli*: characterization of the promoter of the *pstS* gene.** *Mol Gen Genet* 1989, **215**(3):374-380.
11. Makino K, Shinagawa H, Amemura M, Kimura S, Nakata A, Ishihama A: **Regulation of the phosphate regulon of *Escherichia coli*. Activation of *pstS* transcription by PhoB protein in vitro.** *J Mol Biol* 1988, **203**(1):85-95.
12. Makino K, Shinagawa H, Amemura M, Nakata A: **Nucleotide sequence of the *phoB* gene, the positive regulatory gene for the phosphate regulon of *Escherichia coli* K-12.** *J Mol Biol* 1986, **190**(1):37-44.
13. Hulett FM: **The signal-transduction network for Pho regulation in *Bacillus subtilis*.** *Mol Microbiol* 1996, **19**(5):933-939.
14. Sola-Landa A, Rodriguez-Garcia A, Apel AK, Martin JF: **Target genes and structure of the direct repeats in the DNA-binding sequences of the response regulator PhoP in *Streptomyces coelicolor*.** *Nucleic Acids Res* 2008, **36**(4):1358-1368.
15. Steed PM, Wanner BL: **Use of the rep technique for allele replacement to construct mutants with deletions of the *pst-SCAB-phoU* operon: evidence of a new role for the PhoU protein in the phosphate regulon.** *J Bacteriol* 1993, **175**(21):6797-6809.
16. Wang Z, Choudhary A, Ledvina PS, Quijano FA: **Fine tuning the specificity of the periplasmic phosphate transport receptor. Site-directed mutagenesis, ligand binding, and crystallographic studies.** *J Biol Chem* 1994, **269**(40):25091-25094.
17. Martin JF, Marcos AT, Martin A, Asturias JA, Liras P: **Phosphate control of antibiotic biosynthesis at the transcriptional level.** Washington, DC: American Society for Microbiology; 1994.
18. Harris AK, Williamson NR, Slater H, Cox A, Abbasi S, Foulds I, Simonsen HT, Leeper FJ, Salmond GP: **The *Serratia* gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows species- and strain-dependent genome context variation.** *Microbiology* 2004, **150**(Pt 11):3547-3560.
19. Williamson NR, Fineran PC, Ogawa W, Woodley LR, Salmond GP: **Integrated regulation involving quorum sensing, a two-component system, a GGDEF/EAL domain protein and a post-transcriptional regulator controls swarming and RhlA-dependent surfactant biosynthesis in *Serratia*.** *Environ Microbiol* 2008, **10**(5):1202-1217.
20. Manderville RA: **Synthesis, proton-affinity and anti-cancer properties of the prodigiosin-group natural products.** *Curr Med Chem Anti-Canc Agents* 2001, **1**(2):195-218.
21. Perez-Tomas R, Montaner B, Llagostera E, Soto-Cerrato V: **The prodigiosins, proapoptotic drugs with anticancer properties.** *Biochem Pharmacol* 2003, **66**(8):1447-1452.
22. Williamson NR, Fineran PC, Gristwood T, Chawrai SR, Leeper FJ, Salmond GP: **Anticancer and immunosuppressive properties of bacterial prodigines.** *Future Microbiol* 2007, **2**:605-618.
23. Bycroft BW, Maslen C, Box SJ, Brown A, Tyler JW: **The biosynthetic implications of acetate and glutamate incorporation into (3R,5R)-carbapenam-3-carboxylic acid and (5R)-car-**
- bapen-2-em-3-carboxylic acid by *Serratia* sp.** *J Antibiot (Tokyo)* 1988, **41**(9):1231-1242.
24. Parker WL, Rathnun ML, Wells JS Jr, Trejo WH, Principe PA, Sykes RB: **SQ 27,860, a simple carbapenem produced by species of *Serratia* and *Erwinia*.** *J Antibiot (Tokyo)* 1982, **35**(6):653-660.
25. Thomson NR, Crow MA, McGowan SJ, Cox A, Salmond GP: **Biosynthesis of carbapenem antibiotic and prodigiosin pigment in *Serratia* is under quorum sensing control.** *Mol Microbiol* 2000, **36**(3):539-556.
26. Williamson NR, Simonsen HT, Ahmed RA, Goldet G, Slater H, Woodley L, Leeper FJ, Salmond GP: **Biosynthesis of the red antibiotic, prodigiosin, in *Serratia*: identification of a novel 2-methyl-3-n-amyl-pyrrole (MAP) assembly pathway, definition of the terminal condensing enzyme, and implications for undecylprodigiosin biosynthesis in *Streptomyces*.** *Mol Microbiol* 2005, **56**(4):971-989.
27. Williamson NR, Fineran PC, Leeper FJ, Salmond GP: **The biosynthesis and regulation of bacterial prodiginines.** *Nat Rev Microbiol* 2006, **4**(12):887-899.
28. Fineran PC, Slater H, Everson L, Hughes K, Salmond GP: **Biosynthesis of tripyrrole and beta-lactam secondary metabolites in *Serratia*: integration of quorum sensing with multiple new regulatory components in the control of prodigiosin and carbapenem antibiotic production.** *Mol Microbiol* 2005, **56**(6):1495-1517.
29. Slater H, Crow M, Everson L, Salmond GP: **Phosphate availability regulates biosynthesis of two antibiotics, prodigiosin and carbapenem, in *Serratia* via both quorum-sensing-dependent and -independent pathways.** *Mol Microbiol* 2003, **47**(2):303-320.
30. Van Houdt R, Givskov M, Michiels CW: **Quorum sensing in *Serratia*.** *FEMS Microbiol Rev* 2007, **31**(4):407-424.
31. Thomson NR, Cox A, Bycroft BW, Stewart GS, Williams P, Salmond GP: **The rap and hor proteins of *Erwinia*, *Serratia* and *Yersinia*: a novel subgroup in a growing superfamily of proteins regulating diverse physiological processes in bacterial pathogens.** *Mol Microbiol* 1997, **26**(3):531-544.
32. Cathelyn JS, Crosby SD, Lathem WW, Goldman WE, Miller VL: **RovA, a global regulator of *Yersinia pestis*, specifically required for bubonic plague.** *Proc Natl Acad Sci USA* 2006, **103**(36):13514-13519.
33. Ellison DW, Lawrence MB, Miller VL: **Invasin and beyond: regulation of *Yersinia* virulence by RovA.** *Trends Microbiol* 2004, **12**(6):296-300.
34. Nagel G, Lahrz A, Dersch P: **Environmental control of invasin expression in *Yersinia pseudotuberculosis* is mediated by regulation of RovA, a transcriptional activator of the SlyA/Hor family.** *Mol Microbiol* 2001, **41**(6):1249-1269.
35. Fineran PC, Williamson NR, Lilley KS, Salmond GP: **Virulence and prodigiosin antibiotic biosynthesis in *Serratia* are regulated pleiotropically by the GGDEF/EAL domain protein, PigX.** *J Bacteriol* 2007, **189**(21):7653-7662.
36. Gristwood T, Fineran PC, Everson L, Salmond GP: **PigZ, a TetR/AcrR family repressor, modulates secondary metabolism via the expression of a putative four-component resistance-nodulation-cell-division efflux pump, ZrpADBC, in *Serratia* sp. ATCC 39006.** *Mol Microbiol* 2008, **69**(2):418-435.
37. Moura RS, Martin JF, Martin A, Liras P: **Substrate analysis and molecular cloning of the extracellular alkaline phosphatase of *Streptomyces griseus*.** *Microbiology* 2001, **147**(Pt 6):1525-1533.
38. Suziedelienė E, Suziedelis K, Garbenciuviene V, Normark S: **The acid-inducible *asr* gene in *Escherichia coli*: transcriptional control by the *phoBR* operon.** *J Bacteriol* 1999, **181**(7):2084-2093.
39. Lamarche MG, Wanner BL, Crepin S, Harel J: **The phosphate regulon and bacterial virulence: a regulatory network connecting phosphate homeostasis and pathogenesis.** *FEMS Microbiol Rev* 2008, **32**(3):461-473.
40. Martin JF: **Phosphate control of the biosynthesis of antibiotics and other secondary metabolites is mediated by the PhoR-PhoP system: an unfinished story.** *J Bacteriol* 2004, **186**(16):5197-5201.
41. Sola-Landa A, Moura RS, Martin JF: **The two-component PhoR-PhoP system controls both primary metabolism and secondary metabolite biosynthesis in *Streptomyces lividans*.** *Proc Natl Acad Sci USA* 2003, **100**(10):6133-6138.
42. Maplestone RA, Stone MJ, Williams DH: **The evolutionary role of secondary metabolites—a review.** *Gene* 1992, **115**(1):151-157.

43. Vining LC: **Secondary metabolism, inventive evolution and biochemical diversity—a review.** *Gene* 1992, **115**(1–2):135–140.
44. Larsen RA, Wilson MM, Guss AM, Metcalf VVV: **Genetic analysis of pigment biosynthesis in *Xanthobacter autotrophicus* Py2 using a new, highly efficient transposon mutagenesis system that is functional in a wide variety of bacteria.** *Arch Microbiol* 2002, **178**(3):193–201.
45. Herrero A, Flores E: **Transport of basic amino acids by the dinitrogen-fixing cyanobacterium *Anabaena* PCC 7120.** *J Biol Chem* 1990, **265**(7):3931–3935.
46. Bainton NJ, Stead P, Chhabra SR, Bycroft BW, Salmond GP, Stewart GS, Williams P: **N-(3-oxohexanoyl)-L-homoserine lactone regulates carbapenem antibiotic production in *Erwinia carotovora*.** *Biochem J* 1992, **288**(Pt 3):997–1004.
47. de Lorenzo V, Herrero M, Jakubzik U, Timmis KN: **Mini-Tn5 transposon derivatives for insertion mutagenesis, promoter probing, and chromosomal insertion of cloned DNA in gram-negative eubacteria.** *J Bacteriol* 1990, **172**(11):6568–6572.
48. Fineran PC, Everson L, Slater H, Salmond GP: **A GntR family transcriptional regulator (PigT) controls gluconate-mediated repression and defines a new, independent pathway for regulation of the tripyrrole antibiotic, prodigiosin, in *Serratia*.** *Microbiology* 2005, **151**(Pt 12):3833–3845.
49. Lodge J, Fear J, Busby S, Gunasekaran P, Kamini NR: **Broad host range plasmids carrying the *Escherichia coli* lactose and galactose operons.** *FEMS Microbiol Lett* 1992, **74**(2–3):271–276.
50. Sambrook J, Fritsch EF, Maniatis T: **Molecular Cloning: a Laboratory Manual.** 2nd edition. New York, NY: Cold Spring Harbour Laboratory Press; 1989.
51. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: **Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.** *Nucleic Acids Res* 1997, **25**(17):3389–3402.
52. Brickman E, Beckwith J: **Analysis of the regulation of *Escherichia coli* alkaline phosphatase synthesis using deletions and phi80 transducing phages.** *J Mol Biol* 1975, **96**(2):307–316.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

